These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 8823580

  • 1. Tear histamine and histaminase during the early (EPR) and late (LPR) phases of the allergic reaction and the effects of lodoxamide.
    Leonardi AA, Smith LM, Fregona IA, Salmaso M, Secchi AG.
    Eur J Ophthalmol; 1996; 6(2):106-12. PubMed ID: 8823580
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of lodoxamide eye drops on mast cells and eosinophils after allergen challenge in allergic conjunctivitis.
    Bonini S, Schiavone M, Bonini S, Magrini L, Lischetti P, Lambiase A, Bucci MG.
    Ophthalmology; 1997 May; 104(5):849-53. PubMed ID: 9160033
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of lodoxamide eye drops on tear fluid cytology of patients with vernal conjunctivitis.
    Oguz H, Bitiren M, Aslan OS, Ozardali I.
    Acta Med Okayama; 1999 Jun; 53(3):123-6. PubMed ID: 10410789
    [Abstract] [Full Text] [Related]

  • 4. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
    Leonardi A, Abelson MB.
    Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis.
    Avunduk AM, Avunduk MC, Kapicioglu Z, Akyol N, Tavli L.
    Ophthalmology; 2000 Jul; 107(7):1333-7. PubMed ID: 10890862
    [Abstract] [Full Text] [Related]

  • 6. Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Study Group.
    Richard C, Trinquand C, Bloch-Michel E.
    Eur J Ophthalmol; 1998 Jul; 8(4):207-16. PubMed ID: 9891891
    [Abstract] [Full Text] [Related]

  • 7. Effect of lodoxamide on tear leukotriene levels in giant papillary conjunctivitis associated with ocular prosthesis.
    Akman A, Irkeç M, Orhan M, Erdener U.
    Ocul Immunol Inflamm; 1998 Sep; 6(3):179-84. PubMed ID: 9785608
    [Abstract] [Full Text] [Related]

  • 8. Effects of lodoxamide, disodium cromoglycate and fluorometholone on tear leukotriene levels in vernal keratoconjunctivitis.
    Akman A, Irkeç M, Orhan M.
    Eye (Lond); 1998 Sep; 12 ( Pt 2)():291-5. PubMed ID: 9683957
    [Abstract] [Full Text] [Related]

  • 9. Histaminase activity in patients with vernal keratoconjunctivitis.
    Abelson MB, Leonardi AA, Smith LM, Fregona IA, George MA, Secchi AG.
    Ophthalmology; 1995 Dec; 102(12):1958-63. PubMed ID: 9098303
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis.
    Leonardi A, Borghesan F, Avarello A, Plebani M, Secchi AG.
    Br J Ophthalmol; 1997 Jan; 81(1):23-6. PubMed ID: 9135403
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Randomised double-masked trial of lodoxamide and sodium cromoglycate in allergic eye disease. A multicentre study.
    Fahy GT, Easty DL, Collum LM, Benedict-Smith A, Hillery M, Parsons DG.
    Eur J Ophthalmol; 1992 Jan; 2(3):144-9. PubMed ID: 1450659
    [Abstract] [Full Text] [Related]

  • 16. Antiallergic activity of topical lodoxamide on in vivo and in vitro models.
    Ciprandi G, Buscaglia S, Catrullo A, Paolieri F, Riccio AM, Fiorino N, Canonica GW.
    Allergy; 1996 Dec; 51(12):946-51. PubMed ID: 9020426
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of lodoxamide 0.1% versus N-acetyl aspartyl glutamic acid 6% ophthalmic solutions in patients with vernal keratoconjunctivitis.
    Gündüz K, Uçakhan O, Budak K, Eryilmaz T, Ozkan M.
    Ophthalmic Res; 1996 Dec; 28(2):80-7. PubMed ID: 8792357
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis.
    Santos CI, Huang AJ, Abelson MB, Foster CS, Friedlaender M, McCulley JP.
    Am J Ophthalmol; 1994 Apr 15; 117(4):488-97. PubMed ID: 8154531
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological mechanism of topical lodoxamide treatment in vernal keratoconjunctivitis: a flow-cytometric study.
    Avunduk AM, Avunduk MC, Dayanir V, Tekelioğlu Y, Dayioğlu YS.
    Ophthalmic Res; 1998 Apr 15; 30(1):37-43. PubMed ID: 9483586
    [Abstract] [Full Text] [Related]

  • 20. Effect of lodoxamide on in vitro and in vivo conjunctival immediate hypersensitivity responses in rats.
    Yanni JM, Weimer LK, Glaser RL, Lang LS, Robertson SM, Spellman JM.
    Int Arch Allergy Immunol; 1993 Apr 15; 101(1):102-6. PubMed ID: 7684628
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.